# Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

> **NCT07354516** · PHASE2,PHASE3 · RECRUITING · sponsor: **Qlaris Bio, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- OAG - Open-Angle Glaucoma
- OHT - Ocular Hypertension

## Interventions

- **COMBINATION_PRODUCT:** QLS-111-FDC
- **DRUG:** Latanoprost (0.005%)

## Key facts

- **NCT ID:** NCT07354516
- **Lead sponsor:** Qlaris Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07354516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07354516, "Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07354516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*